Physician profile
Abraham Barake
NPI 1962498253
$731.26
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2021: $70.78.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.23 | 2019 | |
| Abbvie INC. | $70.78 | 2021 | |
| Novartis Pharmaceuticals Corporation | $62.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $57.77 | 2019 | |
| Pfizer INC. | $55.20 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $53.16 | 2019 | |
| Arbor Pharmaceuticals, INC. | $49.20 | 2019 | |
| Ge Healthcare | $48.98 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $43.37 | 2019 | |
| Glaxosmithkline, LLC. | $41.02 | 2019 | |
| Aytu Biopharma, INC. | $35.85 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.90 | 2019 | |
| Abbott Laboratories | $18.76 | 2019 | |
| Shire North American Group INC | $17.05 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.85 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $15.24 | 2019 | |
| Amarin Pharma, INC. | $13.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.13 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Barake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.